SciencePower Collaborates to Advance Research on Postbiotics in Breast Cancer Biology
SciencePower, a next-generation postbiotic platform company, today announced that it has entered into a license agreement with Mayo Clinic. The agreement enables collaborative research led by Mayo Clinic investigators to explore the potential of SciencePower’s proprietary postbiotic compositions in breast cancer biology.
The collaboration will focus on understanding how specific microbiome-derived compositions influence immune and cellular pathways relevant to breast cancer. Early preclinical findings are currently planned to be presented at the San Antonio Breast Cancer Symposium (SABCS) in December 2025.
“This milestone marks an important step in validating our technology through rigorous scientific collaboration,” said Robin Albin, SciencePower Co-Founder, Marketing & Communications. “We are honored to work with Mayo Clinic researchers to deepen the understanding of postbiotics and their potential role in advancing human health.”
Mayo Clinic has a financial interest in SciencePower as a result of this agreement. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education, and research.
About SciencePower
SciencePower is a vertically integrated microbiome innovation company pioneering a next-generation class of postbiotics through its proprietary Sequential Fermentation Technology. This patent-pending process mimics the gut’s natural dynamics, producing complex bioactive compositions that support reproducible outcomes in microbiome modulation, gut barrier integrity, and immune balance.
The company is led by a multidisciplinary team with deep expertise in microbiome science, nutrition, fermentation, and the commercialization of health and biotechnology innovations.
SciencePower is currently collaborating with global partners across the nutrition, health, and wellness sectors to develop science-based solutions grounded in microbiome innovation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251208396209/en/
Contacts
Media
robin.albin@sciencepower.com
+1 (914) 391-5081
www.sciencepower.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Furldefense.pro
ofpoint.com%2Fv2%2Furl%3Fu%3Dhttp-3A__www.sciencepower.com_%26d%3DDwMFaQ%26c%3De
uGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM%26r%3Db5HZ97BONBHk-4IRgpfhU5CawOHUAFF
V_NAwBm0itqY%26m%3DD4M9x2W42YRq3xg0e5OPOtHt0OJzeVpPMNltio_e6LFLNtj9YQ8Tf_N1BpTAy
Zr8%26s%3DA2072O_tArsW4CPodyXkSMO5PqBMWWiBX7CK2YUrKc4%26e%3D&esheet=54371686&new
sitemid=20251208396209&lan=en-US&anchor=www.sciencepower.com&index=1&md5=bf26b4b
c2a5979135ee6460df105c94b
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Gulf Oil Selects DataXstream’s OMS+ Portal to Power LATAM Digital Transformation9.12.2025 15:33:00 EET | Press release
DataXstream LLC, an SAP® Endorsed App partner developing innovative solutions for SAP sales and distribution, today announced that Gulf Oil, a globally recognized lubricant company with operations in more than 25 countries, has selected OMS+ Portal to modernize and unify the company’s customer-facing sales platform across Latin America. The project is part of a broader initiative to streamline operations, enhance scalability and deliver a seamless buying experience that is fully integrated with SAP S/4HANA. As Gulf Oil continues its footprint across LATAM, the company needed a solution that would not only elevate the customer experience, but also provide the flexibility and performance needed to scale. OMS+ Portal will serve as the central platform for Gulf’s distributor network, offering a unified, SAP-embedded environment for self-service ordering and real-time collaboration. “We chose OMS+ Portal because it is a certified SAP partner that will help us to scale the customer portal ac
Guardant Health and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy9.12.2025 15:05:00 EET | Press release
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the successful launch of FPG 360, an in-house liquid biopsy testing service at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Policlinico Gemelli) in Rome, Italy. This partnership is the latest in a series of public-private partnerships Guardant Health has formed with top-tier European academic and research hospitals that embed its groundbreaking technology with existing care pathways to expand access to more cancer patients. Policlinico Gemelli will offer on-site liquid biopsy testing based on Guardant360® CDx technology. The collaboration expands access to precision oncology diagnostics and supports both routine care and clinical research. FPG 360 is one of the first dedicated liquid biopsy testing facilities in Italy housed within a hospital system. Policlinico Gemelli, one of Italy's largest and most renowned hospitals, serves thousands of cancer patients each year at its com
Avia Expands to Europe with New German Subsidiary9.12.2025 15:00:00 EET | Press release
AviaGames, a leading global mobile skill-based gaming platform, today announced the establishment of a new subsidiary in Germany. Games industry veteran Michelle Zou has been appointed to head the new entity, overseeing market expansion and investment initiatives across Europe. This move marks a significant milestone in AviaGames’ global growth strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209920028/en/ Games industry veteran Michelle Zou has been appointed to head the AviaGames German subsidiary, overseeing market expansion and investment initiatives across Europe. AviaGames has rapidly emerged as one of the most prominent interactive entertainment companies worldwide, with a global user base of tens of millions of players across North America, and Europe, spanning North America and beyond. The company is especially recognized for its popularity among female players and for delivering high-quality, skill-based
ExaGrid Wins 3 New Industry Awards at the MSP Channel Awards9.12.2025 15:00:00 EET | Press release
ExaGrid®, the industry’s only Tiered Backup Storage solution with AI-Powered Retention Time-Lock (RTL) that includes a non-network-facing tier (tiered air gap), Auto Detect & Guard, delayed deletes and immutability for ransomware recovery, today announced that the company was honored with three awards during the 1st annual MSP Channel Awards ceremony, held in London on December 3, 2025, including: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209577454/en/ Photo courtesy of MSP Channel Awards. Backup & DR Innovation of the Year Storage Hardware Innovation of the Year Storage Vendor of the Year Many Managed Service Providers (MSPs) use ExaGrid Tiered Backup Storage to offer their customers Backup as a Service (BaaS), Disaster Recovery as a Service (DRaaS), and IT Data Center Outsourcing. In 2025, ExaGrid released new features that help MSPs track their customers’ data usage and separately provide the ability to restore an
Aqemia to Attend the 44th Annual J.P. Morgan Healthcare Conference 20269.12.2025 15:00:00 EET | Press release
Aqemia, a drug invention company combining generative AI and quantum-inspired physics, announces it will attend and hold 1x1 meetings at the 44th Annual J.P. Morgan Healthcare Conference, taking place at The Westin St. Francis in San Francisco from January 12 to 15, 2026. Aqemia will be represented by Maximilien Levesque, CEO and co-founder, Emmanuelle Martiano, COO and co-founder, and Théa Vu-Bignand, VP Finance. Powered by QEMI, its proprietary physics-based generative AI engine for therapeutic molecule invention, Aqemia designs novel drug candidates in a repeatable, efficient, and scalable way. The company focuses on advancing its internal preclinical pipeline while establishing partnerships that validate its platform and scientific differentiation, with the ambition to accelerate the delivery of new therapies in areas of high unmet medical need. About Aqemia Aqemia is a drug invention company dedicated to creating novel molecules to address unmet medical needs. Its proprietary QEMI
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom